Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Apr 29, 2016

Color Genomics' Color Test

Color Genomics has launched the Color Test, a new hereditary cancer risk assessment test. The panel analyzes 30 genes:  BAP1, MITF, CDK4, CDKN2A, ATM, CDH1, NBN, CHEK2, PTEN, BRCA1, BRCA2, PALB2, BARD1, BRIP1, TP53, STK11, MLH1, MSH2, EPCAM, MSH6, PMS2, RAD51C, RAD51D, APC, BMPR1A, SMAD4, GREM1, MUTYH, POLD1, POLE. These genes affect hereditary cancer risks for breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers in both men and women. The company said it has validated the test in studies with the University of Washington and the University of California, San Francisco.

Macrogen's MyPetgene Genetic Testing

Macrogen has launched MyPetgene, a customized genetic testing service that provides information on rare genetic disorders that may occur in various species of animals, individual DNA identification, and breed and gender verification. The tests analyze the genes of various companion animals such as dogs, horses, birds, and cats, and provides information that can predict and help manage potential genetic disorders in advance, the company said. Once customers receive the kit, they must return it with buccal epithelial cells, blood, hairs, bone fraction, and other samples. Once the tests are completed, the results are available on the MyPetgene website within three days.

Hematogenix FDA Approved PD-L1 Companion Diagnostic Tests

Hematogenix Laboratory Services is offering two US Food and Drug Administration approved PD-L1 companion diagnostic assays: PD-L1 IHC 22C3 pharmDx for Keytruda and PD-L1 IHC 28-8 pharmDx. Dako, an Agilent company, developed PD-L1 IHC 22C3 pharmDx Keytruda in partnership with Merck. Keytruda is approved by the FDA to treat patients with metastatic non-small cell lung cancer whose tumors express PD-L1 and have disease progression on or after platinum-containing chemotherapy. PD-L1 IHC 28-8 pharmDx, also developed by Dako, was approved as a companion diagnostic for Bristol-Myers Squibb's Opdivo, to detect PD-L1 protein expression levels and to help physicians determine which patients may benefit most from treatment with the therapy. Both kits are available through Dako.

For more new products and services, please visit the New Products page on our website.